

Product Datasheet

PABP Antibody (10E10) - BSA Free NB120-6125SS

Unit Size: 0.025 ml

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Reviews: 1 Publications: 11

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NB120-6125

Updated 9/9/2025 v.20.1

**Earn rewards for product
reviews and publications.**

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NB120-6125



NB120-6125SS


PABP Antibody (10E10) - BSA Free

Product Information	
Unit Size	0.025 ml
Concentration	1.0 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Monoclonal
Clone	10E10
Preservative	0.02% Sodium Azide
Isotype	IgG2b
Purity	Protein G purified
Buffer	PBS
Target Molecular Weight	69 kDa
Product Description	
Description	Novus Biologicals Mouse PABP Antibody (10E10) - BSA Free (NB120-6125) is a monoclonal antibody validated for use in WB, ELISA, Flow, ICC/IF and IP. Anti-PABP Antibody: Cited in 11 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Mouse
Gene ID	26986
Gene Symbol	PABPC1
Species	Human, Bovine, Canine, Primate, Xenopus, Drosophila (Negative), Mouse (Negative)
Reactivity Notes	Does not cross-react with Drosophila melanogaster or Mouse. Not yet tested in other species.
Immunogen	Recombinant human PABP protein. [Uniprot# P11940]
Product Application Details	
Applications	Western Blot, ELISA, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunoprecipitation, Microarray, CyTOF-ready
Recommended Dilutions	Western Blot 1:1000, Flow Cytometry, ELISA 1:100-1:2000, Immunocytochemistry/ Immunofluorescence 1:50-1:100, Immunoprecipitation 1:10-1:500, Microarray, CyTOF-ready
Application Notes	The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. This antibody is CyTOF ready.




Images


Western Blot: PABP Antibody (10E10) [NB120-6125] - Analysis of PABP expression in 1) A-431, 2) HeLa and 3) NIH-3T3 whole cell lysates.




Immunocytochemistry/Immunofluorescence: PABP Antibody (10E10) [NB120-6125] - PABP antibody was tested in HeLa cells at a 1:50 dilution using a Dylight 488 conjugated secondary antibody (Green). Actin (Red) and DNA (Blue) were counterstained using Phalloidin 568 and DAPI.




Flow Cytometry: PABP Antibody (10E10) [NB120-6125] - An intracellular stain was performed on A431 cells with PABP [10E10] Antibody NB120-6125AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.




Western Blot: PABP Antibody (10E10) [NB120-6125] - Cell line lysates were separated on SDS-PAGE and probed with 1 ug/mL Monoclonal Anti-PABP Clone: 10E10. The antibody was developed using Goat Anti-Mouse IgG-Peroxidase and a chemiluminescent substrate. (1) HEK293T, (2) HeLa, (3) G361 and (4) COS-7.




PI3K/AKT signaling contributes to HG-induced PABP expression, which promotes DENV infection. (A) Western blot showed the expression of PABP, NF90, hnRNP, eEF1A, PTB, YB-1, and β -actin in 5.5 or 25 mM glucose (Glu) medium-treated BHK-21 cells for 48 hours. (B) Furthermore, the time course expression of PABP protein also is shown. (C) Western blot showed PABP protein expression in BHK-21 cells that were pretreated with or without PI3K inhibitor (LY294002), the mTOR inhibitor rapamycin (Rapa), or AKT inhibitor (AKTi) for 1 hour followed by 5.5 or 25 mM Glu-containing-medium treatment for 48 hours. (D) Real-time qPCR assays showed the expression of PABP mRNA in 5.5 or 25 mM Glu-treated BHK-21 cells that were pretreated with or without LY294002 and an AKTi for 1 hour and subsequently maintained in medium containing 5.5 or 25 mM Glu for 48 hours. (E) Western blot showed PABP protein expression in BHK-21 cells pretreated with PABP siRNA (siPABP) for 48 hours, followed by incubation with medium containing 25 mM Glu. Cells without control siRNA pretreatment were used as negative control. (F) Plaque assays were conducted to determine the viral titer of BHK-21 cells that were pretreated with PABP siRNA for 48 hours and then infected with DENV 2 (MOI, 1) for an additional 48 hours in 5.5 or 25 mM Glu-containing medium. DMSO was used as a control. The mean \pm SD of quantitative data from at least 3 independent experiments are reported. ** $P < 0.01$, *** $P < 0.001$. RQ, relative quantification. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36125898>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



PI3K/AKT signaling contributes to HG-induced PABP expression, which promotes DENV infection. (A) Western blot showed the expression of PABP, NF90, hnRNP, eEF1A, PTB, YB-1, and β -actin in 5.5 or 25 mM glucose (Glu) medium-treated BHK-21 cells for 48 hours. (B) Furthermore, the time course expression of PABP protein also is shown. (C) Western blot showed PABP protein expression in BHK-21 cells that were pretreated with or without PI3K inhibitor (LY294002), the mTOR inhibitor rapamycin (Rapa), or AKT inhibitor (AKTi) for 1 hour followed by 5.5 or 25 mM Glu-containing-medium treatment for 48 hours. (D) Real-time qPCR assays showed the expression of PABP mRNA in 5.5 or 25 mM Glu-treated BHK-21 cells that were pretreated with or without LY294002 and an AKTi for 1 hour and subsequently maintained in medium containing 5.5 or 25 mM Glu for 48 hours. (E) Western blot showed PABP protein expression in BHK-21 cells pretreated with PABP siRNA (siPABP) for 48 hours, followed by incubation with medium containing 25 mM Glu. Cells without control siRNA pretreatment were used as negative control. (F) Plaque assays were conducted to determine the viral titer of BHK-21 cells that were pretreated with PABP siRNA for 48 hours and then infected with DENV 2 (MOI, 1) for an additional 48 hours in 5.5 or 25 mM Glu-containing medium. DMSO was used as a control. The mean \pm SD of quantitative data from at least 3 independent experiments are reported. ** $P < 0.01$, *** $P < 0.001$. RQ, relative quantification. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36125898>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



PI3K/AKT signaling contributes to HG-induced PABP expression, which promotes DENV infection. (A) Western blot showed the expression of PABP, NF90, hnRNP, eEF1A, PTB, YB-1, and β -actin in 5.5 or 25 mM glucose (Glu) medium-treated BHK-21 cells for 48 hours. (B) Furthermore, the time course expression of PABP protein also is shown. (C) Western blot showed PABP protein expression in BHK-21 cells that were pretreated with or without PI3K inhibitor (LY294002), the mTOR inhibitor rapamycin (Rapa), or AKT inhibitor (AKTi) for 1 hour followed by 5.5 or 25 mM Glu-containing-medium treatment for 48 hours. (D) Real-time qPCR assays showed the expression of PABP mRNA in 5.5 or 25 mM Glu-treated BHK-21 cells that were pretreated with or without LY294002 and an AKTi for 1 hour and subsequently maintained in medium containing 5.5 or 25 mM Glu for 48 hours. (E) Western blot showed PABP protein expression in BHK-21 cells pretreated with PABP siRNA (siPABP) for 48 hours, followed by incubation with medium containing 25 mM Glu. Cells without control siRNA pretreatment were used as negative control. (F) Plaque assays were conducted to determine the viral titer of BHK-21 cells that were pretreated with PABP siRNA for 48 hours and then infected with DENV 2 (MOI, 1) for an additional 48 hours in 5.5 or 25 mM Glu-containing medium. DMSO was used as a control. The mean \pm SD of quantitative data from at least 3 independent experiments are reported. ** $P < 0.01$, *** $P < 0.001$. RQ, relative quantification. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36125898>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Shen TJ, Chen CL, Tsai TT et al. Hyperglycemia exacerbates dengue virus infection by facilitating poly(A)-binding protein-mediated viral translation JCI Insight 2022-11-08 [PMID: 36125898] (Western Blot, Mouse)

Nagel M, Noß M, Xu J et al. The kinesin motor KIF1C is a putative transporter of the exon junction complex in neuronal cells bioRxiv 2022-08-26 [PMID: 36316088] (WB, Human)

Kim B, Park Y, Hwang HJ et al. Single polysome analysis of mRNP Biochemical and biophysical research communications 2022-06-08 [PMID: 35716598]

Genois MM, Gagné JP, Yasuhara T, et al. CARM1 regulates replication fork speed and stress response by stimulating PARP1 Molecular cell 2020-12-30 [PMID: 33412112]

Sagliocco F, Laloo B, Cosson B et al. The ARE-associated factor AUF1 binds poly(A) in vitro in competition with PABP. Biochem J. 2006-12-01 [PMID: 16834569] (WB, Mouse)

Grosset C, Chen CY, Xu N et al. A mechanism for translationally coupled mRNA turnover: interaction between the poly(A) tail and a c-fos RNA coding determinant via a protein complex. Cell. 2000-09-29 [PMID: 11051545] (WB, Mouse)

Larralde O, Smith RW, Wilkie GS et al. Direct stimulation of translation by the multifunctional herpesvirus ICP27 protein. J Virol. 2006-02-01 [PMID: 16415034] (WB, Human)

Nelson PT, Hatzigeorgiou AG, Mourelatos Z. miRNP:mRNA association in polyribosomes in a human neuronal cell line. RNA. 2004-03-01 [PMID: 14970384] (WB, Human)

Sladic RT, Lagnado CA, Bagley CJ, Goodall GJ. Human PABP binds AU-rich RNA via RNA-binding domains 3 and 4. Eur J Biochem. 2004-01-01 [PMID: 14717712] (IP, Human)

Lee J, Bedford MT. PABP1 identified as an arginine methyltransferase substrate using high-density protein arrays. EMBO Rep. 2002-03-01 [PMID: 11850402] (IP, Human)

Chazal PE, Dagueuet E, Wendling C et al. EJC core component MLN51 interacts with eIF3 and activates translation Proc Natl Acad Sci U S A 2013-03-25 [PMID: 23530232] (WB, Human)



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-
techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB120-6125

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

